Inspire Medical Systems, Inc. (INSP) Q3 2024 Earnings Call Transcript Summary
Inspire Medical Systems, Inc. (INSP) Q3 2024 Earnings Call Transcript Summary
Net income for Q3 was $18.5 million, a significant improvement from a net loss of $8.5 million in Q3 2023, with earnings per share at $0.60.The following is a summary of the Inspire Medical Systems, Inc. (INSP) Q3 2024 Earnings Call Transcript:
以下是Inspire Medical Systems, Inc. (INSP) Q3 2024 業績會 記要:
Financial Performance:
金融業績：
Inspire Medical Systems reported a Q3 2024 revenue of $203.2 million, marking a 33% year-over-year increase.
U.S. revenue was $195.8 million, reflecting a 33% increase compared to the same period last year.
Net income for Q3 was $18.5 million, a significant improvement from a net loss of $8.5 million in Q3 2023, with earnings per share at $0.60.
The company raised its full-year revenue guidance to $793 million to $798 million, indicating a 27% to 28% growth over 2023.
Adjusted full-year earnings per share guidance was revised upwards to $1.20 to $1.40.
Inspire Medical Systems報告Q3 2024年營業收入爲20320萬美元，同比增長33%。
美國營業收入爲19580萬美元，較去年同期增長33%。
Q3的淨利潤爲1850萬美元，同比2023年Q3的850萬美元淨虧損有了顯著改善，每股收益爲0.60美元。
該公司將全年營收指引提升至79300萬至79800萬美元，預示着2023年同比增長27%至28%。
調整後的全年每股收益指引上調至1.20至1.40美元。
Business Progress:
業務進展：
Inspire Medical Systems surpassed 85,000 patients receiving therapy and expanded into 66 new implanting centers and 13 new U.S. sales territories.
The company introduced digital scheduling tools across 250 centers to streamline appointment bookings and enhance patient experience.
Plans are underway for a soft launch of the new Inspire V neurostimulation system in late 2024, with full availability expected in 2025.
Continued investment in medical education programs, with over 250 advanced practice providers trained and an expected additional 70 by year-end.
inspire medical systems已經超過了85,000名接受治療的患者，並擴展到了66個新的植入中心和13個新的美國銷售領土。
該公司在250箇中心推出了數字化預約工具，以簡化預約並提升患者體驗。
計劃在2024年底軟推出新款inspire V神經刺激系統，預計將在2025年全面推廣。
持續投資於醫學教育項目，已有250多名高級實踐提供者接受培訓，預計到年底還將增加70名。
Opportunities:
機會：
Anticipated market expansion and adoption of Inspire therapy in France and the UK, alongside strengthening positions in Germany, Switzerland, the Netherlands, and Belgium.
The pending introduction of the Inspire V system, which simplifies the surgical process and is expected to broaden the therapy's appeal.
Increasing awareness and diagnostic rates of obstructive sleep apnea, potentially boosted by societal trends and other diagnostic technologies.
預計市場在法國和英國擴大並採用inspire療法，同時加強在德國、瑞士、荷蘭和比利時的地位。
即將推出inspire V系統，簡化手術流程，預計將拓寬該療法的適用範圍。
推動阻塞性睡眠呼吸暫停症的認知度和診斷率提高，這可能受社會趨勢和其他診斷技術的推動。
Risks:
風險：
Potential revenue headwinds in Q4 2024 due to hurricanes and IV solution shortages impacting operations and patient scheduling.
由於颶風和靜脈注射溶液短缺影響業務和患者排班，預計2024年第四季度可能面臨營業收入上行壓力。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
